Outpatient Performed Pterygium Surgery Study (NCT03037736) | Clinical Trial Compass
WithdrawnPhase 4
Outpatient Performed Pterygium Surgery Study
Stopped: Funding not received.
0Started 2020-03-01
Plain-language summary
This is a randomized controlled trial of postoperative bevacizumab or 5-fluorouracil subconjunctival injections vs placebo for the recurrence of pterygia after excision using conjunctival autograft.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with symptomatic single-headed primary pterygia extending 2mm or more onto the cornea and determined by the physician to be a good candidate for surgical excision.
* Able to express a basic understanding of the study as determined by the treating physician.
* Age 18 and older.
* Commitment to return for follow up visits
Exclusion Criteria:
* Patients who are pregnant or who are planning on becoming pregnant during the study period
* Patients who are unable to tolerate subconjunctival injections in the clinic setting
* Patients with a diagnosis of glaucoma who are on more than 1 topical medication to control their intraocular pressure or who have ocular hypertension with a pressure of greater than or equal to 24mmHg.
* Patients with a previous history of conjunctival surgery in the eye with the pterygium
* Patients with a history of autoimmune or inflammatory conjunctival or corneal disorders, including but not limited to Stevens Johnson syndrome, graft versus host disease, mucous membrane pemphigoid, severe atopy, and herpes simplex epitheliitis or keratitis.
* Patients with an allergy to one or more of the study drugs.
* Patients who are on systemic immunosuppressive therapy or chemotherapy.
* Patients with a condition requiring topical steroid drops in the study eye or oral prednisone at a dose of more than 5mg/day.
* Patients with a history of scleritis or other severe ocular surface disease such as limbal stem cell deficiency.
* Patients …